Advancements in Molecular Residual Disease Testing Offer New Insights for Breast Cancer Treatment
Recent developments in the field of precision oncology have highlighted the potential of Molecular Residual Disease (MRD) testing in managing triple-negative breast cancer (TNBC), one of the most aggressive breast cancer subtypes. According to findings presented at the American Association for Cancer Research Annual Meeting, MRD testing, particularly through the use of circulating tumor DNA (ctDNA) status, provides significant insights into treatment response and recurrence risk. The study, part of the NSABP-B-59/GBG-96-GeparDouze trial, revealed that patients who were ctDNA-negative after neoadjuvant therapy were more likely to achieve a pathologic complete response at surgery. Conversely, those who remained ctDNA-positive faced a higher risk of distant recurrence. This testing method offers a new layer of biological insight beyond traditional imaging and pathology, which often cannot detect microscopic disease post-treatment. 
